@article{SCI10632,
author = {Kazuhito Naka and Tatsuo Ichinohe},
title = {New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment},
journal = {Stem Cell Investigation},
volume = {3},
number = {6},
year = {2016},
keywords = {},
abstract = {Although the discovery of tyrosine kinase inhibitors (TKIs) has dramatically improved the prognoses of chronic myelogenous leukemia (CML) patients, a cure has remained elusive. Unanswered questions include how long must a patient continue on TKI therapy, and how does a patient know when he/she can safely stop or finish this therapy? Imagawa et al. have carefully addressed these questions of safety and efficacy using a stop study of the second-generation TKI dasatinib. The results of a multicenter phase II trial termed the “dasatinib discontinuation” (DADI) trial indicated that 48% (30/63) of CML patients who had maintained a deep molecular response (DMR) to second-line or subsequent dasatinib therapy for at least for 1 year did not show any signs of disease relapse. Thus, even after it is stopped, dasatinib treatment may decrease the chance of disease relapse and provide a curative benefit to CML patients. This work by Imagawa et al. strongly supports the clinical utility of the second-generation TKI dasatinib for CML treatment.},
issn = {2313-0792}, url = {https://sci.amegroups.org/article/view/10632}
}